These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7476093)

  • 21. [Establishment and experimental study on mouse model of Chlamydia pneumoniae pneumonitis].
    Shi Y; Yin J; Zhan H
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Oct; 24(10):592-5. PubMed ID: 11770419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic and mucosal antibody response in experimental Chlamydia pneumoniae infection of mice.
    Penttilä T; Wahlström E; Vuola JM; Sarvas M; Puolakkainen M
    Comp Med; 2006 Aug; 56(4):272-8. PubMed ID: 16941954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal models for Chlamydia pneumoniae infection.
    Saikku P; Laitinen K; Leinonen M
    Atherosclerosis; 1998 Oct; 140 Suppl 1():S17-9. PubMed ID: 9859920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential for vaccine development against chlamydial infection and disease.
    Brunham RC; Zhang DJ; Yang X; McClarty GM
    J Infect Dis; 2000 Jun; 181 Suppl 3():S538-43. PubMed ID: 10839755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chlamydia pneumoniae infection in mice induces chronic lung inflammation, iBALT formation, and fibrosis.
    Jupelli M; Shimada K; Chiba N; Slepenkin A; Alsabeh R; Jones HD; Peterson E; Chen S; Arditi M; Crother TR
    PLoS One; 2013; 8(10):e77447. PubMed ID: 24204830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chlamydia pneumoniae replicates in Kupffer cells in mouse model of liver infection.
    Marangoni A; Donati M; Cavrini F; Aldini R; Accardo S; Sambri V; Montagnani M; Cevenini R
    World J Gastroenterol; 2006 Oct; 12(40):6453-7. PubMed ID: 17072977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chlamydia pneumoniae infection in asthmatic patients.
    Araafa RM; Matta AM; Bassuny EA; Gad NM; Anan A
    Egypt J Immunol; 2003; 10(1):103-9. PubMed ID: 15719627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice.
    Törmäkangas L; Saario E; Bem David D; Bryskier A; Leinonen M; Saikku P
    J Antimicrob Chemother; 2004 Jun; 53(6):1101-4. PubMed ID: 15117927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.
    Törmäkangas L; Alakärppä H; David DB; Leinonen M; Saikku P
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3655-61. PubMed ID: 15388416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IgG subclass-specific antibodies in Chlamydia pneumoniae infections.
    Anttila T; Leinonen M; Surcel HM; Von Hertzen L; Bloigu A; Seppälä I; Saikku P
    Scand J Infect Dis; 1998; 30(4):381-6. PubMed ID: 9817519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neutralization of interleukin-17 aggravates respiratory infection induced by Chlamydia trachomatis in mice].
    Zhang XY; Li Q; Zhang YQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Aug; 45(4):613-8. PubMed ID: 23939174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model.
    Penttilä T; Tammiruusu A; Liljeström P; Sarvas M; Mäkelä PH; Vuola JM; Puolakkainen M
    Vaccine; 2004 Sep; 22(25-26):3386-94. PubMed ID: 15308363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae.
    Rodríguez A; Rottenberg M; Tjärnlund A; Fernández C
    Scand J Immunol; 2006 Mar; 63(3):177-83. PubMed ID: 16499570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Isolation of Chlamydia pneumoniae from a patient with acute bronchitis].
    Kanamoto Y; Sakano T
    Kansenshogaku Zasshi; 1992 May; 66(5):637-42. PubMed ID: 1402098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation and role of IFN-gamma in the innate resistance to infection with Chlamydia pneumoniae.
    Rottenberg ME; Gigliotti Rothfuchs A; Gigliotti D; Ceausu M; Une C; Levitsky V; Wigzell H
    J Immunol; 2000 May; 164(9):4812-8. PubMed ID: 10779789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chlamydia pneumoniae infection in IL-10 knock out mice: accelerated clearance but severe pulmonary inflammatory response.
    Penttilä T; Haveri A; Tammiruusu A; Vuola JM; Lahesmaa R; Puolakkainen M
    Microb Pathog; 2008 Jul; 45(1):25-9. PubMed ID: 18456450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toll-like receptors 2 and 4 do not contribute to clearance of Chlamydophila pneumoniae in mice, but are necessary for the release of monokines.
    Mueller M; Postius S; Thimm JG; Gueinzius K; Muehldorfer I; Hermann C
    Immunobiology; 2004; 209(8):599-608. PubMed ID: 15638128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental infection by Chlamydia pneumoniae in the hamster.
    Sambri V; Donati M; Storni E; Di Leo K; Agnusdei M; Petracca R; Finco O; Grandi G; Ratti G; Cevenini R
    Vaccine; 2004 Mar; 22(9-10):1131-7. PubMed ID: 15003640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein.
    Pal S; Bravo J; Peterson EM; de la Maza LM
    Infect Immun; 2008 Dec; 76(12):5581-7. PubMed ID: 18809664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine response of lymphocytes persistently infected with Chlamydia pneumoniae.
    Takano R; Yamaguchi H; Sugimoto S; Nakamura S; Friedman H; Yamamoto Y
    Curr Microbiol; 2005 Mar; 50(3):160-6. PubMed ID: 15883875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.